Revance Therapeutics (RVNC) Raised to Buy at ValuEngine

ValuEngine upgraded shares of Revance Therapeutics (NASDAQ:RVNC) from a hold rating to a buy rating in a research report released on Tuesday.

A number of other research analysts have also commented on the stock. Cantor Fitzgerald set a $50.00 price objective on shares of Revance Therapeutics and gave the company a buy rating in a research report on Thursday, August 2nd. JMP Securities lowered shares of Revance Therapeutics from an outperform rating to a market perform rating in a research report on Monday, September 17th. BidaskClub lowered shares of Revance Therapeutics from a hold rating to a sell rating in a research report on Saturday, September 15th. Zacks Investment Research raised shares of Revance Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 9th. Finally, Piper Jaffray Companies reaffirmed a buy rating on shares of Revance Therapeutics in a research report on Monday, September 17th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $47.10.

Shares of RVNC traded up $0.77 during trading hours on Tuesday, reaching $23.92. 240,531 shares of the company traded hands, compared to its average volume of 302,057. The firm has a market capitalization of $917.91 million, a P/E ratio of -5.97 and a beta of 1.30. Revance Therapeutics has a 1-year low of $22.25 and a 1-year high of $37.45.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.02). The company had revenue of $0.69 million for the quarter, compared to analyst estimates of $0.93 million. Revance Therapeutics had a negative net margin of 13,690.62% and a negative return on equity of 63.30%. Equities research analysts predict that Revance Therapeutics will post -3.9 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Northern Trust Corp increased its stake in Revance Therapeutics by 22.5% in the second quarter. Northern Trust Corp now owns 415,856 shares of the biopharmaceutical company’s stock valued at $11,415,000 after acquiring an additional 76,406 shares during the period. Sio Capital Management LLC bought a new stake in Revance Therapeutics in the second quarter valued at about $2,780,000. MetLife Investment Advisors LLC increased its stake in Revance Therapeutics by 41.5% in the second quarter. MetLife Investment Advisors LLC now owns 15,532 shares of the biopharmaceutical company’s stock valued at $426,000 after acquiring an additional 4,557 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in Revance Therapeutics by 25.8% in the second quarter. Metropolitan Life Insurance Co. NY now owns 10,875 shares of the biopharmaceutical company’s stock valued at $299,000 after acquiring an additional 2,232 shares during the period. Finally, Cubist Systematic Strategies LLC increased its stake in Revance Therapeutics by 43.2% in the second quarter. Cubist Systematic Strategies LLC now owns 8,795 shares of the biopharmaceutical company’s stock valued at $241,000 after acquiring an additional 2,654 shares during the period. 94.35% of the stock is currently owned by institutional investors and hedge funds.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Recommended Story: Exchange-Traded Funds (ETFs)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply